专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07723107B2 Pharmaceutical composition for inducing an immune response in a human or animal 有权
标题翻译：用于在人或动物中诱导免疫应答的药物组合物
公开(公告)号：US07723107B2
公开(公告)日：2010-05-25
申请号：US12182089
申请日：2008-07-29
申请人： Alexei Kirkin , Karine Djandjougazian , Jesper Zeuthen
发明人： Alexei Kirkin , Karine Djandjougazian , Jesper Zeuthen
IPC分类号： C12N5/08
CPC分类号： A61K39/0011 , A61K2039/5154 , A61K2039/5158 , C12N5/0639 , C12N2501/22 , C12N2501/23 , C12N2501/25
摘要： The present invention relates to a pharmaceutical composition for inducing an immune response in a human or animal, comprising dendritic cells loaded with at least five cancer/testis antigen and no lineage specific differentiation antigens or substantially no lineage specific differentiation antigens provided from at least one cancer cell line, as well as to isolated cell lines expressing a multiplicity of cancer testis antigens and no differentiation antigens, and to a method of inducing an immune response in a human or animal using the composition of the invention.
摘要翻译：本发明涉及一种用于在人或动物中诱导免疫应答的药物组合物，其包含负载至少五种癌/睾丸抗原并且没有谱系特异性分化抗原的树突状细胞或基本上不存在至少一种癌症提供的谱系特异性分化抗原细胞系，以及表达多种癌睾丸抗原和分化抗原的分离的细胞系，以及使用本发明的组合物在人或动物中诱导免疫应答的方法。

2. 发明申请

US20060051324A1 Pharmaceutical composition for inducing an immune response in a human or animal 有权
标题翻译：用于在人或动物中诱导免疫应答的药物组合物
公开(公告)号：US20060051324A1
公开(公告)日：2006-03-09
申请号：US10495511
申请日：2002-11-29
申请人： Alexei Kirkin , Karine Djandjougazian , Jesper Zeuthen
发明人： Alexei Kirkin , Karine Djandjougazian , Jesper Zeuthen
IPC分类号： C12N5/06 , A61K35/14
CPC分类号： A61K39/0011 , A61K2039/5154 , A61K2039/5158 , C12N5/0639 , C12N2501/22 , C12N2501/23 , C12N2501/25
摘要： The present invention relates to a pharmaceutical composition for inducing an immune response in a human or animal, comprising dendritic cells loaded with at least five cancer/testis antigen and no lineage specific differentiation antigens or substantially no lineage specific differentiation antigens provided from at least one cancer cell line, as well as to isolated cell lines expressing a multiplicity of cancer testis antigens and no differentiation antigens, and to a method of inducing an immune response in a human or animal using the composition of the invention.
摘要翻译：本发明涉及一种用于在人或动物中诱导免疫应答的药物组合物，其包含负载至少五种癌/睾丸抗原并且没有谱系特异性分化抗原的树突状细胞或基本上不存在至少一种癌症提供的谱系特异性分化抗原细胞系，以及表达多种癌睾丸抗原和分化抗原的分离的细胞系，以及使用本发明的组合物在人或动物中诱导免疫应答的方法。

3. 发明授权

US07771998B2 Pharmaceutical composition for inducing an immune response in a human or animal 有权
公开(公告)号：US07771998B2
公开(公告)日：2010-08-10
申请号：US10495511
申请日：2002-11-29
申请人： Alexei Kirkin , Karine Djandjougazian , Jesper Zeuthen
发明人： Alexei Kirkin , Karine Djandjougazian , Jesper Zeuthen
IPC分类号： C12N5/071 , A01N63/00
CPC分类号： A61K39/0011 , A61K2039/5154 , A61K2039/5158 , C12N5/0639 , C12N2501/22 , C12N2501/23 , C12N2501/25
摘要： The present invention relates to a pharmaceutical composition for inducing an immune response in a human or animal, comprising dendritic cells loaded with at least five cancer/testis antigen and no lineage specific differentiation antigens or substantially no lineage specific differentiation antigens provided from at least one cancer cell line, as well as to isolated cell lines expressing a multiplicity of cancer testis antigens and no differentiation antigens, and to a method of inducing an immune response in a human or animal using the composition of the invention.

4. 发明授权

US5206144A Determination of glycated (glycosylated) hemoglobin in blood 失效
标题翻译：测定血液中糖化（糖基化）血红蛋白
公开(公告)号：US5206144A
公开(公告)日：1993-04-27
申请号：US607766
申请日：1990-10-30
申请人： Jesper Zeuthen , Annette Prento , Viggo Kruse
发明人： Jesper Zeuthen , Annette Prento , Viggo Kruse
IPC分类号： C07K16/18 , G01N33/72
CPC分类号： G01N33/723 , C07K16/18
摘要： The concentration of glycated hemoglobin, HbA.sub.1c, in hemoglobin from diabetic patients is regarded as a useful means of assessing the adequacy of diabetes control. This invention comprises a monoclonal antibody which, due to its specific binding of HbA.sub.1c, can be used for the determination of HbA.sub.1c in the absence of prior denaturation, in blood samples by such analytical methods as radioimmuno assay or enzyme-linked immunosorbent assay. The invention also comprises hybridoma cell lines which produce monoclonal antibodies of the invention.
摘要翻译：糖尿病患者血红蛋白中糖化血红蛋白HbA1c的浓度被认为是评估糖尿病控制适宜性的有用手段。本发明包括一种单克隆抗体，由于其具有HbA1c的特异性结合，可以通过放射免疫测定法或酶联免疫吸附测定法等分析方法在血液样品中不用先前变性来测定HbA1c。本发明还包括产生本发明的单克隆抗体的杂交瘤细胞系。

5. 发明授权

US4816441A Peptides and compositions 失效
标题翻译：肽和组合物
公开(公告)号：US4816441A
公开(公告)日：1989-03-28
申请号：US930481
申请日：1986-11-14
申请人： Jesper Zeuthen , Lars Thim , Niels P. H. Moller
发明人： Jesper Zeuthen , Lars Thim , Niels P. H. Moller
IPC分类号： C12P21/02 , A61K35/74 , A61K38/00 , C07K1/20 , C07K7/06 , C07K7/08 , C07K14/00 , C07K14/195 , C07K14/31 , C07K14/41 , C07K14/52 , A61K37/02 , C07K7/10
CPC分类号： C07K14/31 , A61K38/00
摘要： Peptides of the formula R.sup.1 -His-Asp-Glu-Ala-R wherein R.sup.1 is Ala-Gln, and R is a polypeptide residue with up to 50 amino acid residues, and wherein one, more or all of the amino acid residues in R.sup.1 and/or R independently may be omitted, can be used to augment cell mediated cytotoxicity and thereby to treat cancers and viral infections. These peptides may be prepared by proteolytic digestion of Staphylococcus aureus protein A, as well as by protein synthesis, recombinant DNA methods or any other methods known in the art.
摘要翻译：式R1-His-Asp-Glu-Ala-R的肽，其中R1是Ala-Gln，R是具有至多50个氨基酸残基的多肽残基，并且其中R1中的一个，多个或全部的氨基酸残基和/或R独立地可以省略，可以用于增加细胞介导的细胞毒性，从而治疗癌症和病毒感染。这些肽可以通过金黄色葡萄球菌蛋白A的蛋白水解消化，以及通过蛋白质合成，重组DNA方法或本领域已知的任何其它方法来制备。

6. 发明授权

US09771558B2 Method for generating dendritic cells employing decreased temperature 有权
公开(公告)号：US09771558B2
公开(公告)日：2017-09-26
申请号：US12086050
申请日：2006-12-07
申请人： Alexei Kirkin , Karine Djandjougazian , Jesper Zeuthen
发明人： Alexei Kirkin , Karine Djandjougazian , Jesper Zeuthen
IPC分类号： A61K35/12 , C12N5/00 , C12N5/0784 , A61K39/00
CPC分类号： C12N5/0639 , A61K2039/5154 , C12N2501/22 , C12N2501/23 , C12N2501/25 , C12N2523/00
摘要： The invention relates in certain embodiments to a method for generating dendritic cells by employing temperatures below 37° C. during the development of progenitor cells and immature dendritic cells. In some embodiments the invention relates to populations of dendritic cells and its use.

7. 发明申请

US20090029457A1 PHARMACEUTICAL COMPOSITION FOR INDUCING AN IMMUNE RESPONSE IN A HUMAN OR ANIMAL 有权
标题翻译：用于诱导人类或动物免疫应答的药物组合物
公开(公告)号：US20090029457A1
公开(公告)日：2009-01-29
申请号：US12182089
申请日：2008-07-29
申请人： Alexei KIRKIN , Karine Djandjougazian , Jesper Zeuthen
发明人： Alexei KIRKIN , Karine Djandjougazian , Jesper Zeuthen
IPC分类号： C12N5/00
CPC分类号： A61K39/0011 , A61K2039/5154 , A61K2039/5158 , C12N5/0639 , C12N2501/22 , C12N2501/23 , C12N2501/25
摘要： The present invention relates to a pharmaceutical composition for inducing an immune response in a human or animal, comprising dendritic cells loaded with at least five cancer/testis antigen and no lineage specific differentiation antigens or substantially no lineage specific differentiation antigens provided from at least one cancer cell line, as well as to isolated cell lines expressing a multiplicity of cancer testis antigens and no differentiation antigens, and to a method of inducing an immune response in a human or animal using the composition of the invention.
摘要翻译：本发明涉及一种用于在人或动物中诱导免疫应答的药物组合物，其包含负载至少五种癌/睾丸抗原并且没有谱系特异性分化抗原的树突状细胞或基本上不存在至少一种癌症提供的谱系特异性分化抗原细胞系，以及表达多种癌睾丸抗原和分化抗原的分离的细胞系，以及使用本发明的组合物在人或动物中诱导免疫应答的方法。

8. 发明授权

US5175113A Modified .beta..sub.2 -microglobulin 失效
标题翻译：改良的β2-微球蛋白
公开(公告)号：US5175113A
公开(公告)日：1992-12-29
申请号：US550919
申请日：1990-03-29
申请人： Mogens H. Nissen , Jesper Zeuthen , Flemming S. Larsen , Lars Thim , Mogens Christensen
发明人： Mogens H. Nissen , Jesper Zeuthen , Flemming S. Larsen , Lars Thim , Mogens Christensen
IPC分类号： A61K38/00 , C07K14/74 , C07K16/28 , G01N33/68
CPC分类号： C07K14/70539 , C07K16/2833 , G01N33/6893 , A61K38/00 , Y10S436/804
摘要： Substantially pure modified .beta..sub.2 -microglobulin (m.beta..sub.2 m) of the formula I ##STR1## wherein R.sub.1 is 24-amino acid residue, with the sequence Ile-Gln-Arg-Thr-Pro-Lys-Ile-Gln-Val-Tyr-Ser-Arg-His-Pro-Ala-Glu-Asn-Gly-Lys-Ser-Asn-Phe-Leu-Asn, R.sub.2 is a 30-amino acid residue with the sequence Tyr-Val-Ser-Gly-Phe-His-Pro-Ser-Asp-Ile-Glu-Val-Asp-Leu-Leu-Lys-Asn-Gly-Glu-Arg-Ile-Gly-Lys-Val-Glu-His-Ser-Asp-Leu-Ser, R.sub.3 is a 20-amino acid residue with the sequence Trp-Ser-Phe-Tyr-Leu-Leu-Tyr-Tyr-Glu-Phe-Thr-Pro-Thr-Glu-Lys-Asp-Glu-Tyr-Ala, R.sub.4 is a 19-amino acid residue with the sequence Arg-Val-Asn-His-Val-Thr-Leu-Ser-Gln-Pro-Lys-Ile-Val-Lys-Trp-Asp-Arg-Asp-Met, X is Phe, Phe-Ser, or Phe-Ser-Lys, and Y is Asp, Lys-Asp, or Ser-Lys-Asp is disclosed. The presence of the protein in body fluids is a diagnostic and/or prognostic marker for the development of a variety of disorders such as different types of cancer and diseases involving the immune system. Also disclosed are specific anti-m.beta..sub.2 m antibodies used for the detection and quantification of m.beta..sub.2 m.
摘要翻译：其中R1是24个氨基酸残基的具有Ile-Gln-Arg-Thr-Pro-Lys-Ile-Gln-Val-Tyr序列的基本上纯的经修饰的β2-微球蛋白（mβ2m） -Ser-Arg-His-Pro-Ala-Glu-Asn-Gl y-Lys-Ser-Asn-Phe-Leu-Asn，R2是30-氨基酸残基，具有序列Tyr-Val-Ser-Gly-Phe -His-Pro-Ser-Asp-Ile-Glu-Val-Asp-Leu-Leu-Lys-Asn-Gl y-Glu-Arg-Ile-Gly-Lys-Val-Glu-His-Ser-Asp-Leu- Ser，R3是具有序列Trp-Ser-Phe-Tyr-Leu-Leu-Tyr-Tyr-Glu-Phe-Thr-Pro-Thr-Glu-Lys-Asp-Glu-Tyr- Ala，R4是序列Arg-Val-Asn-His-Val-Thr-Leu-Ser-Gln-Pro-Lys-Ile-Val-Lys-Trp-Asp-Arg-As p- Met，X是Phe，Phe-Ser或Phe-Ser-Lys，Y是Asp，Lys-Asp或Ser-Lys-Asp。体液中蛋白质的存在是用于发展各种疾病如诊断和/或预后的标志物，例如不同类型的癌症和涉及免疫系统的疾病。还公开了用于检测和定量m 2 m的特异性抗-mβ2m抗体。

9. 发明申请

US20090196856A1 Method for Generating Dendritic Cells Employing Decreased Temperature 有权
标题翻译：生产降低温度的树突细胞的方法
公开(公告)号：US20090196856A1
公开(公告)日：2009-08-06
申请号：US12086050
申请日：2006-12-07
申请人： Alexei Kirkin , Karine Djandjougazian , Jesper Zeuthen
发明人： Alexei Kirkin , Karine Djandjougazian , Jesper Zeuthen
IPC分类号： A61K35/12 , C12N5/00 , A61P37/00 , A61P35/00 , A61P31/00
CPC分类号： C12N5/0639 , A61K2039/5154 , C12N2501/22 , C12N2501/23 , C12N2501/25 , C12N2523/00
摘要： The invention relates in certain embodiments to a method for generating dendritic cells by employing temperatures below 37° C. during the development of progenitor cells and immature dendritic cells. In some embodiments the invention relates to populations of dendritic cells and its use.
摘要翻译：本发明在某些实施方案中涉及通过在祖细胞和未成熟树突状细胞的开发期间使用低于37℃的温度产生树突状细胞的方法。在一些实施方案中，本发明涉及树突状细胞群及其用途。

10. 发明授权

US5051371A Modified .beta..sub.2 -microglobulin 失效
标题翻译：改良的β2-微球蛋白
公开(公告)号：US5051371A
公开(公告)日：1991-09-24
申请号：US3436
申请日：1987-01-15
申请人： Mogens H. Nissen , Jesper Zeuthen , Flemming S. Larsen , Lars Thim , Mogens Christensen
发明人： Mogens H. Nissen , Jesper Zeuthen , Flemming S. Larsen , Lars Thim , Mogens Christensen
IPC分类号： C07K14/005 , A61K38/00 , A61K38/16 , A61K39/00 , A61P37/00 , C07K14/00 , C07K14/195 , C07K14/435 , C07K14/74 , C07K16/00 , C07K16/28 , C07K19/00 , C12P21/08 , G01N33/534 , G01N33/569 , G01N33/577 , G01N33/68
CPC分类号： G01N33/6893 , C07K14/70539 , C07K16/2833 , A61K38/00 , C07K2317/34 , Y10S530/811 , Y10S530/812 , Y10S530/864
摘要： Substantially pure modified .beta..sub.2 -microglobulin (m.beta..sub.2 m) of the formula I ##STR1## wherein R.sub.1 is 24-amino acid residue, with the sequence Ile-Gln-Arg-Thr-Pro-Lys-Ile-Gln-Val-Tyr-Ser-Arg-His-Pro-Ala-Glu-Asn-Gly-Lys-Ser-Asn-Phe-Leu-Asn, R.sub.2 is a 30-amino acid residue with the sequence Tyr-Val-Ser-Gly-Phe-His-Pro-Ser-Asp-Ile-Glu-Val-Asp-Leu-Leu-Lys-Asn-Gly-Glu-Arg-Ile-Gly-Lys-Val-Glu-His-Ser-Asp-Leu-Ser, R.sub.3 is a 20-amino acid residue with the sequence Trp-Ser-Phe-Tyr-Leu-Leu-Tyr-Tyr-Glu-Phe-Thr-Pro-Thr-Glu-Lys-Asp-Glu-Tyr-Ala, R.sub.4 is a 19-amino acid residue with the sequence Arg-Val-Asn-His-Val-Thr-Leu-Ser-Gln-Pro-Lys-Ile-Val-Lys-Trp-Asp-Arg-Asp-Met, X is Phe, Phe-Ser, or Phe-Ser-Lys, and Y is Asp, Lys-Asp, or Ser-Lys-Asp is disclosed. The presence of the protein in body fluids is a diagnostic and/or prognostic marker for the development of a variety of disorders such as different types of cancer and diseases involving the immune system. Also disclosed are specific anti-m.beta..sub.2 m antibodies used for the detection and quantification of m.beta..sub.2 m.
摘要翻译：具有Ile-Gln-Arg-Thr-Pro-Lys-Ile-Gln-Val-I的序列的基本上纯的经修饰的β2-微球蛋白（mβ2m），其中R1是24-氨基酸残基， Tyr-Ser-Arg-His-Pro-Ala-Glu-Asn-Gl y-Lys-Ser-Asn-Phe-Leu-Asn，R2是具有序列Tyr-Val-Ser-Gly- Phe-His-Pro-Ser-Asp-Ile-Glu-Val-Asp-Leu-Leu-Lys-Asn-Gl y-Glu-Arg-Ile-Gly-Lys-Val-Glu-His-Ser-Asp-Leu -Ser，R3是具有序列Trp-Ser-Phe-Tyr-Leu-Leu-Tyr-Tyr-Glu-Phe-Thr-Pro-Thr-Glu-Lys-Asp-Glu-Tyr的20个氨基酸残基 -Ala，R4是具有序列Arg-Val-Asn-His-Val-Thr-Leu-Ser-Gln-Pro-Lys-Ile-Val-Lys-Trp-Asp-Arg-Asp的19个氨基酸残基 -Met，X是Phe，Phe-Ser或Phe-Ser-Lys，Y是Asp，Lys-Asp或Ser-Lys-Asp。体液中蛋白质的存在是用于发展各种疾病如诊断和/或预后的标志物，例如不同类型的癌症和涉及免疫系统的疾病。还公开了用于检测和定量m 2 m的特异性抗-mβ2m抗体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式